Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye
Paul Hahn Duke Eye Center, Duke University Medical Center, Durham, NC, USA Abstract: Intravitreal anti-vascular endothelial growth factor (VEGF) pharmacotherapy in vitrectomized eyes remains a challenge due to the reduced half-life of these agents. Aflibercept may have stronger binding activity a...
Saved in:
Main Author: | Hahn P |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2014
|
Subjects: | |
Online Access: | https://doaj.org/article/ac166e2228324f9db5ad66860dfbfcda |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
by: Nudleman E, et al.
Published: (2016) -
Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab [Corrigendum]
by: Nudleman E, et al.
Published: (2017) -
One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
by: Tran THC, et al.
Published: (2021) -
Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
by: Garweg JG
Published: (2019) -
Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration
by: Thomas M, et al.
Published: (2013)